During the past decade, Care Access conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Care Access" are "Nonalcoholic Fatty Liver Disease" (1 trials) and "Primary Biliary Cholangitis" (1 trials). Many other conditions were trialed in "Care Access" in a lesser frequency.

Most popular intervention types in "Care Access" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Seladelpar 10 mg" (1 trials), "Seladelpar 5 mg" (1 trials) and "TVB-2640" (1 trials). Other intervention names were less common.

The vast majority of trials in "Care Access" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Care Access". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Care Access, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Care Access, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".